Bio View

Bio View 40. noteikums

40. noteikums no Bio View (BIOV.TA) uz 2026. g. 26. okt. ir -62,13 %. Iepriekšējā gadā 40. noteikums bija -37,42 % — izmaiņas 66,05 % (zemāks).

40. noteikums

-62,13 %

YoY

66,05%

Pēdējoreiz atjaunināts:

40. noteikums no Bio View ir 2025 -62,13 % . 40. noteikums no Bio View bija 2024 -37,42 % . Tas samazinās par 66,05% zemāks salīdzinājumā ar iepriekšējo gadu.

Bio View 40. noteikums vēsture

  • 3 gadi

  • 10 gadi

  • 25 gadi

  • Max

40. noteikums
Datums
40. noteikums
2018. g. 1. janv.
-15,92 ILS
2019. g. 1. janv.
51,06 ILS
2020. g. 1. janv.
-22,84 ILS
2021. g. 1. janv.
27,21 ILS
2022. g. 1. janv.
0,41 ILS
2023. g. 1. janv.
21,49 ILS
2024. g. 1. janv.
-37,42 ILS
2025. g. 1. janv.
-62,13 ILS
Bio View 40. noteikums vēsture
GADS40. noteikumsYoY
-62,13 %+66,05%
-37,42 %-274,10%
21,49 %+5105,71%
0,41 %-98,48%
27,21 %-219,12%
-22,84 %-144,73%
51,06 %-420,82%
-15,92 %-26,65%
-21,70 %-304,29%
10,62 %-58,06%
25,33 %—

Iegūstiet šos datus caur Eulerpool API

100 000 pieprasījumu/mēn. bez maksas · bez kartes

Bio View Akciju analīze

Ko dara Bio View? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par Bio View akciju

Bio View 40. noteikums 2025. gadā ir -62,13 %.

Vietnē Eulerpool varat atrast pilnīgu 40. noteikums Bio View vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

40 noteikums paredz, ka uzņēmuma ieņēmumu izaugsmes temps plus peļņas marža jāpārsniedz 40%. Tas tiek plaši izmantots SaaS un augstas izaugsmes uzņēmumu novērtēšanai.

Iegūstiet šos datus caur Eulerpool API

100 000 pieprasījumu/mēn. bez maksas · bez kartes

Kvalitāte — Bio View

Visas kategorijas